- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00297804
A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions (TAXUS VI)
TAXUS VI - A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The ultimate goal of a paclitaxel eluting stent system is to prevent restenosis by blunting the initial response to stent implant injury and sustaining the arrested response until vascular healing has taken place.
The purpose of the TAXUS VI trial is to study the safety and efficacy of the TAXUS(TM)Stent under controlled trial circumstances and targets patients with a higher risk of target lesion revascularisation and restenosis. The study population will include longer lesions, smaller diameter vessels, multiple lesions in the same vessel, and allows for the use of up to 2 randomized study stents.
The clinical investigation will evaluate the safety and effectiveness of the TAXUS(TM)Stent with 1 µg/mm2 (loaded drug/stent surface area) of paclitaxel incorporated into a moderate rate-release formulation of a triblock copolymer carrier system for treatment of de novo coronary artery lesions.
Patients are stratified by site and presence or absence of medically treated diabetes mellitus and then randomized to receive either the TAXUS(TM)Stent or the uncoated EXPRESS(TM)stent.
The primary objective of the study is to show superior 9-month target vessel revascularization (TVR) rate for TAXUS(TM) Stent compared to uncoated Express(TM)control stent.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Siegburg, Germany, 53721
- HELIOS Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General Inclusion Criteria
- Patient >or= 18 years old
- Eligible for percutaneous coronary intervention
- Documented stable angina pectoris or unstable angina pectoris with documented ischemia or documented silent ischemia
- Acceptable candidate for CABG
- Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
- Willing to comply with all specified follow-up evaluations
Angiographic Inclusion Criteria
- Target lesion located within a single native coronary vessel
- Target lesion randomized to treatment with the study device may be composed of multiple lesions but must be completely coverable by up to 2 study stents (maximum allowable stent length of 48 mm).
- Cumulative target lesion length is >or= 18 mm and <or= 40 mm (visual estimate)
- RVD of >or= 2.5 mm to <or= 3.75 mm (visual estimate)
- Target lesion diameter stenosis >or=50% (visual estimate)
- Target lesion is de novo
Exclusion Criteria:
General Exclusion Criteria:
- Known sensitivity to paclitaxel
- Any previous or planned treatment with any anti-restenotic drug-coated or drug-eluting coronary stent (Note: previous or planned treatment with heparin or phosphorylcholine coated stents is acceptable, as long as the procedure with the stent meets the protocol defined criteria for staged procedures)
- Previous or planned treatment with intravascular brachytherapy in the target vessel
- MI within 72 hours prior to the study procedure and/or CK-MB >2x the local laboratory's upper limits of normal (refers to a measured value on the day of the study procedure)
- Left ventricular ejection fraction <25%
- Cerebrovascular Accident within the past 6 months
- Acute or chronic renal dysfunction (creatinine >1.7 mg/dl or >150 µmol/L)
- Contraindication to ASA, or to both clopidogrel and ticlopidine
- Leukopenia (leukocyte count <3.5 x 109/liter)
- Thrombocytopenia (platelet count <100,000/mm3)
- Active peptic ulcer or active gastrointestinal bleeding
- Known allergy to stainless steel
- Any prior true anaphylactic reaction to contrast agents
- Known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the study procedure
- Patient is currently taking colchicine
- Patient is currently, or has been treated with paclitaxel within 12 months of the study procedure
- Female of childbearing potential with a positive pregnancy test within 7 days before the study procedure, or lactating, or intends to become pregnant during the study
- Life expectancy of less than 24 months due to other medical conditions
- Co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
- Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
Angiographic Exclusion Criteria
- Left main coronary artery disease (stenosis >50%), whether protected or unprotected
- Target lesion is ostial in location (within 3.0 mm of vessel origin)
- Target lesion(s) and/or target vessel proximal to the target lesion(s) is moderately or severely calcified by visual estimation
- Target lesion is located within or distal to a >60°bend in the vessel
- Target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >2.0 mm in diameter
- Target lesion is totally occluded Thrombolysis in MI (TIMI flow <or= 1)
- Angiographic presence of probable or definite thrombus
- Target vessel will be pre-treated with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 2
|
control stent
|
Experimental: Arm 1
|
Paclitaxel-Eluting Coronary Stent System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of TVR 9 months after index procedure
Time Frame: 9 Months
|
9 Months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
• Rates of composite Major Adverse Cardiac Events (MACE) and the individual components of MACE, assessed at 1, 3, 6 and 9 months after the study procedure and annually for 5 years (i.e., 1, 2, 3, 4, and 5 years after the study procedure).
Time Frame: 5 years
|
5 years
|
Stent thrombosis rate.
Time Frame: 5 Years
|
5 Years
|
Target Vessel Failure.
Time Frame: 5 years
|
5 years
|
Clinical procedural success.
Time Frame: Post procedure
|
Post procedure
|
Binary restenosis rate.
Time Frame: 9 months
|
9 months
|
• Additional angiographic endpoints at 9 month angiographic follow-up
Time Frame: 9 months
|
9 months
|
IVUS assessment in a subset of approximately 200 patients. At the baseline procedure (post-procedural) and at 9 month follow-up the absolute neointimal volume and the change in neointimal volume from post-procedure to follow-up will be analysed.
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eberhard Grube, MD, HELIOS Clinic Siegburg, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- S2009
- TAXUS VI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on TAXUS Express Paclitaxel-Eluting Coronary Stent System
-
Boston Scientific CorporationCompletedCoronary Artery DiseaseUnited States, Australia, New Zealand, Singapore
-
Medtronic VascularCompletedCardiovascular Diseases | Coronary Artery Disease | Arteriosclerosis | Ischemic Heart Disease | Stenotic Coronary LesionChina
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery RestenosisUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary RestenosisNetherlands, Spain, Denmark, Germany, France, Austria, Belgium, India, Italy, New Zealand, Poland, South Africa, Switzerland
-
Abbott Medical DevicesCompletedCoronary Artery DiseaseUnited States
-
North Texas Veterans Healthcare SystemUS Department of Veterans Affairs; University of Arkansas; Michael E. DeBakey... and other collaboratorsCompletedArteriosclerosis | Coronary Artery BypassUnited States, Greece
-
Cordis CorporationConor MedsystemsTerminatedCoronary AtherosclerosisBrazil, New Zealand
-
Medical University of ViennaCompleted
-
Cordis CorporationConor MedsystemsCompletedCoronary DiseaseUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary RestenosisNew Zealand, Australia, Germany, France, Switzerland, Netherlands, United Kingdom, Portugal, Belgium, Denmark